News

Milestone Scientific Gains Approval for Federal Supply Schedule

Milestone Scientific Gains Approval for Federal Supply Schedule

Milestone Scientific's Key Approval for CompuFlo® System

Milestone Scientific Inc. (MLSS), a prominent name in the medical technology industry, has recently achieved a significant milestone by securing approval for the Federal Supply Schedule (FSS) concerning its CompuFlo® Epidural System. This news marks a substantial step for the company, which specializes in developing cutting-edge computerized drug delivery instruments designed to deliver painless and precise injections. The FSS approval provides Milestone with pre-negotiated pricing and a premium position as a pre-vetted contractor, enhancing its ability to provide federal agencies with innovative medical solutions.

Understanding the Federal Supply Schedule

The FSS, commonly referred to as the GSA Schedule, is a vital procurement tool utilized by various government agencies. By being included in this schedule, Milestone Scientific can facilitate streamlined purchasing processes for its products, specifically the CompuFlo® Epidural System and its associated consumables. The initial phase of the FSS contract extends over a five-year term, with the potential to be renewed for additional five-year intervals, creating a pathway for up to 20 years of access to government buyers.

Innovative Technology at Work

The CompuFlo® Epidural System employs Milestone's proprietary Dynamic Pressure Sensing Technology, which provides real-time feedback during epidural procedures. This innovative solution is engineered to ensure precise needle placement, significantly elevating patient safety and comfort levels. By reducing complications associated with traditional epidural techniques, Milestone is setting a new standard in pain management and procedural efficacy.

Expanding Opportunities in Federal Healthcare

With the FSS contract now in place, Milestone Scientific stands poised to expand its reach into key segments of the federal healthcare market. This includes major federal healthcare providers such as the Department of Defense (DoD), the Department of Veterans Affairs (VA), and the Indian Health Service (IHS).

Targeting the Veterans Health Administration

The Veterans Health Administration operates the largest integrated healthcare system in the United States, addressing the needs of nearly 9.1 million enrolled veterans. Given that a significant portion of these veterans struggle with chronic pain, the deployment of the CompuFlo® Epidural System could play a pivotal role in enhancing their care and comfort.

Impacts on the Department of Defense

The Military Health System (MHS) under the DoD serves around 9.5 million beneficiaries, including active military personnel and their families. With a substantial percentage experiencing chronic pain, there is a crucial demand for effective pain management solutions, making Milestone's offerings timely and valuable.

Reaching American Indian Communities via the IHS

The Indian Health Service offers healthcare to 2.8 million American Indians and Alaska Natives. Many individuals receiving care through this system experience chronic pain, demonstrating the necessity for effective pain relief technologies like the CompuFlo® Epidural System.

Leadership Insight from Milestone Scientific

Arjan Haverhals, CEO of Milestone Scientific, expressed optimism regarding this federal contract. He stated, "Securing approval on the Federal Supply Schedule is pivotal for our vision to transform epidural procedures. Our technology not only demonstrates clinical efficacy but also stands as a gateway to becoming a committed partner for federal healthcare systems. This will allow us to improve patient access to our groundbreaking solutions." We have invested considerable effort into preparing for this milestone, focusing on building partnerships and a robust pipeline of opportunities within the VA, DoD, and IHS. With this approval now granted, our team is ready to collaborate with key stakeholders to foster adoption of the CompuFlo® Epidural System and enhance patient experiences across these vital healthcare sectors." Haverhals also acknowledged the crucial support received from Kandu Supplies and Services LLC and Shamrock Medical LLC, who facilitated the achievement of this important milestone.

About Milestone Scientific Inc.

Milestone Scientific Inc. (MLSS) is a technology-driven medical R&D firm that specializes in developing innovative injection technologies and medical instruments. Their focus lies on ensuring that injections are not only precise and efficient but also prioritize patient comfort and safety. With their cutting-edge computer-controlled systems, Milestone Scientific is advancing the future of medical injections. Their proprietary Dynamic Pressure Sensing Technology serves as a foundation for developing next-gen devices aimed at enhancing drug delivery methods.

Frequently Asked Questions

What is the significance of the FSS approval for Milestone Scientific?

The FSS approval allows Milestone Scientific to sell its CompuFlo® Epidural System to government agencies with pre-negotiated pricing, significantly enhancing access to their products.

How does the CompuFlo® Epidural System work?

This system utilizes Dynamic Pressure Sensing Technology to provide real-time feedback during epidural procedures, ensuring accurate needle placement and improving patient safety.

What healthcare sectors can benefit from Milestone's technology?

The technology is especially beneficial to the Department of Veterans Affairs, Department of Defense, and Indian Health Service, all of which serve populations that frequently experience chronic pain.

Who is the CEO of Milestone Scientific?

The CEO of Milestone Scientific is Arjan Haverhals, who has been instrumental in guiding the company's innovative strategies.

What is the mission of Milestone Scientific?

Milestone Scientific aims to revolutionize medical injections and epidural procedures through innovative technologies that enhance the overall patient experience and safety.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Intelligent Communication Forum Eyes Global Ecosystem Shift

Updated Category News Views 627

China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...

Continue Reading
Gildan's Crisis: Investors Face Losses Amid Lawsuit

Updated Category News Views 245

Gildan Investors, Brace Yourself Poor old Gildan Activewear finds itself in hot water again, with a class action lawsuit cropping up like an unexpected storm on farmers' day. Any traders remotely involved with NYSE:GIL should pay damn close attention, because with a December 14, 2026 deadline looming, it's crunch time. The Root of the Lawsuit The plot thickens here,...

Continue Reading
ASTS Faces Class Action; Investors Beware of Pitfalls

Updated Category News Views 311

Securities Fraud Allegations Hit AST SpaceMobile Days like this remind me why we keep our eyes peeled in the stock game—AST SpaceMobile (NASDAQ: ASTS) is tangled in a web of legal drama, and it's something you can't brush off with a shrug. Class action lawsuits for securities fraud? That's like finding out the foundation's shaky beneath a skyscraper. If you've got skin...

Continue Reading
LG's ASIL D Certification: A Game Changer in Autos

Updated Category News Views 150

Why LG's ASIL D Certification Matters There ain't much in the tangled mess of automotive innovations these days that'll make a seasoned investor raise an eyebrow, but here comes LG Electronics grabbing the ASIL D certification like it's a badge of market honor. The ISO 26262 ASIL D is no walk in the park, folks—it's the top rung on the safety ladder, something that's...

Continue Reading
D-Wave's Legal Trouble: Securities Fraud Suit Looms

Updated Category News Views 364

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...

Continue Reading
CureGene's Evategrel Aims for Breakthrough in Stroke Care

Updated Category News Views 105

Revolutionizing Stroke Care: Enter Evategrel When it comes to strokes, time is money—and I'm telling you, this ain't an area where you can afford to twiddle your thumbs. The faster you can get that blood flowing again, the better the chance you've got of walking away with less damage. That's where CureGene's new investigational drug, Evategrel, comes in. Why Evategrel...

Continue Reading
GlycoNex Eyes Japanese Market with Denosumab Biosimilar

Updated Category News Views 108

A Strategic Step into the Japanese Market Alright folks, there's a new kid aiming to shake things up in the biotech neighborhood, and it's GlycoNex with its denosumab biosimilar, SPD8. These guys just tossed their hat in the ring with a regulatory submission to Japan's Pharmaceuticals and Medical Devices Agency (PMDA). If the cosmic forces align, they might snag an...

Continue Reading
Cleaner Air in Bedroom May Stabilize Blood Sugar Levels

Updated Category News Views 354

Imagine a world where simply sleeping in cleaner air could affect your blood sugar. Seems far-fetched, I know. But that's where we're at with this new study out of NYU Langone Health. They're talking about using plain ol' portable air filters to help steady blood sugar levels for folks dealing with prediabetes. Turns out a cleaner bedroom might just hold the key to taming...

Continue Reading
Fibocom Unveils U6G Solutions Advancing Global 5G Tech

Updated Category News Views 35

Breaking Barriers with U6G-Capable Technology Sneaking into the industry's spotlight at MWC Doha 2026, Fibocom flaunts a robust lineup of next-gen 5G solutions. It's as if they're shuffling every card they’ve got to win over the broadband world. With breakthroughs like the FG390, FG370, and FG670 modules, alongside PCBA-level innovations, Fibocom is not just throwing...

Continue Reading
Novo's Semaglutide Shows Promise in MASH Study

Updated Category News Views 364

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Continue Reading

Top 5 Most Recently Viewed Articles

VIQ Solutions' Leadership Transition Marks New Era Ahead

Updated Category News Views 244

VIQ Solutions Marks a New Chapter with Leadership Changes VIQ Solutions Inc. is making noteworthy changes in its executive team that will undoubtedly shape the organization's path forward. The firm, known for being a global provider of AI-driven, secure digital voice and video capture technology, has announced the retirement of Susan Sumner, who has been a pivotal figure...

Continue Reading
Lucid Group's Fourth Quarter Success: Record Deliveries Ahead

Updated Category News Views 130

Lucid Group Inc Reports Strong Q4 Earnings Lucid Group Inc (NASDAQ: LCID) has revealed its fourth-quarter financial results, demonstrating a significant improvement in revenue and production metrics. The results were reported after the market closed on a recent Tuesday, showcasing the company's ongoing commitment to innovation in the electric vehicle sector. Revenue...

Continue Reading
Verily Sightline Collaborates with Bangor University in Europe

Updated Category News Views 149

Verily Partners with Bangor University for Wastewater Testing Verily, recognized for its precision health technology, is extending its wastewater surveillance program into Europe through a promising partnership with Bangor University. This collaboration aims to take advantage of the innovative wastewater-based public health programs at Bangor to enhance testing...

Continue Reading
Amaero's Strategic Supply Agreement Boosts U.S. Titanium Production

Updated Category News Views 213

Amaero Secures Strategic Long-Term Supply Agreement Significant Milestone in Domestic Supply Chain Development Amaero International Limited (ASX:3DA), a prominent U.S. manufacturer of high-quality titanium powders, has successfully signed a three-year Supply Agreement with The Perryman Company, a leader in titanium production. This agreement marks a pivotal moment in...

Continue Reading
NextPlat: Insights from Interim CEO on Future Directions

Updated Category News Views 132

NextPlat Corp's Interim CEO Update NextPlat Corp (NASDAQ: NXPL), a prominent player in the consumer products and services sector, recently issued a pivotal update from its interim CEO, David Phipps. This detailed letter serves as a roadmap to navigate the company’s future after the unexpected passing of its former CEO, Charles M. Fernandez. The focus is on leveraging...

Continue Reading